当前位置:首页 - 行情中心 - 华仁药业(300110) - 财务分析 - 利润表

华仁药业

(300110)

  

流通市值:34.02亿  总市值:34.05亿
流通股本:11.81亿   总股本:11.82亿

利润表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、营业总收入309,965,165.171,321,454,092.38976,270,444.55623,896,434.45
  营业收入309,965,165.171,321,454,092.38976,270,444.55623,896,434.45
二、营业总成本289,559,960.821,204,460,892.77908,109,518.39580,297,334.96
  营业成本206,903,941.21831,915,880.14642,895,832.33388,481,128.59
  税金及附加5,534,190.721,663,256.8715,891,847.1910,593,727.41
  销售费用30,631,620.5150,362,677.61101,306,237.9383,111,639.18
  管理费用22,786,352.7690,393,682.1565,861,447.7244,679,018.12
  研发费用14,080,034.4567,825,661.6348,370,181.9529,961,200.24
  财务费用9,623,821.242,299,734.3733,783,971.2723,470,621.42
  其中:利息费用9,356,759.3641,969,585.5931,590,965.0121,235,172.89
  其中:利息收入53,030.79523,301.92287,103.27239,406.96
三、其他经营收益
  加:投资收益-44,283.194,815,796.522,281,821.82,298,173.26
  资产处置收益07,332.4900
  资产减值损失(新)9,557.52-563,219,531.8-1,112,415.07-1,112,415.07
  信用减值损失(新)546,574.58-22,904,890.73-13,968,652.22-10,469,832.22
  其他收益1,989,472.948,612,828.17,322,078.127,523,266.03
四、营业利润22,906,526.2-455,695,265.8162,683,758.7941,838,291.49
  加:营业外收入46,753.142,568,119.112,180,154.492,149,924.94
  减:营业外支出2,873,983.485,814,169.11,585,943.861,140,657.34
五、利润总额20,079,295.86-458,941,315.863,277,969.4242,847,559.09
  减:所得税费用3,275,886.86447,7605,879,952.993,682,578.47
六、净利润16,803,409-459,389,075.857,398,016.4339,164,980.62
(一)按经营持续性分类
  持续经营净利润16,803,409-459,389,075.857,398,016.4339,164,980.62
(二)按所有权归属分类
  归属于母公司股东的净利润15,958,601.73-462,900,017.6354,579,793.8537,332,883.17
  少数股东损益844,807.273,510,941.832,818,222.581,832,097.45
  扣除非经常损益后的净利润16,512,325.85-470,281,564.1145,727,165.6527,689,155.59
七、每股收益
  (一)基本每股收益0.01-0.390.050.03
  (二)稀释每股收益0.01-0.390.050.03
九、综合收益总额16,803,409-459,389,075.857,398,016.4339,164,980.62
  归属于母公司股东的综合收益总额15,958,601.73-462,900,017.6354,579,793.8537,332,883.17
  归属于少数股东的综合收益总额844,807.273,510,941.832,818,222.581,832,097.45
公告日期2026-04-242026-04-242025-10-302025-08-16
审计意见(境内)标准无保留意见
TOP↑